For medical device manufacturers scoping a study in France, Germany or the UK: not a rule of thumb, not "0.8x the CRO budget", but a line-by-line CRO and site-cost forecast built from real hospital tariffs. Three scenarios, compared side by side, modelled live on Milo TF. Your first budget within 48 hours.
Whatever you searched for, the answer is the same engine: real hospital tariffs, real CRO rates, three scenarios per country. Pick the brief closest to yours.
Most CRO quotes give a project total and a hand-wave on site fees. We do the opposite: every site grant is assembled from the real cost drivers in a European hospital, priced from a live tariff database, and reflows as you change the design.
The fully loaded cost of the people who run the visits. Research nurses, study coordinators, pharmacy and back-office time, at the real per-hour rate negotiated in each country.
Investigator and clinician time priced explicitly, not buried in an overhead. Per-hour and per-visit rates for the PI, sub-investigators and adjudication, by country and by specialty.
MRI (IRM) and X-ray priced per scan, at the real hospital tariff in each geography, plus reading and central-upload time. The imaging burden becomes a visible, costed line, not a surprise.
The comparison sponsors never get from a CRO: the same study, costed line by line against the real tariffs of each country. The structure below illustrates a mid-size cardiovascular study. Your workshop produces these numbers against your real protocol.
| Cost componentrepresentative unit | FranceEUR € | GermanyEUR € | United KingdomGBP £ |
|---|---|---|---|
| Research nurseper hour, fully loaded | ~€55 | ~€65 | ~£50 |
| Clinician / PIper hour | ~€180 | ~€210 | ~£170 |
| MRI / IRMper scan, incl. reading | ~€280 | ~€420 | ~£350 |
| X-rayper scan | ~€45 | ~€70 | ~£60 |
| Screening visitnurse + clinician + admin | ~€520 | ~€640 | ~£560 |
| Pharmacy set-upper site | ~€4,500 | ~€6,000 | ~£5,200 |
| Per-patient site grantall visits, fully costed | ~€9,800 | ~€12,400 | ~£11,000 |
Sample figures shown blurred. For a mid-size cardiovascular study, around 250 patients across 18 sites, these unit costs roll up to roughly €4.0M (swift), €5.4M (base) and €7.6M (conservative). Your real, unblurred per-country numbers are built live against your protocol when you book.
For each country, Milo TF produces three scenarios, anchored to seven years of delivery data. The numbers move as you adjust the inputs, on screen, in the workshop.
P75 site recruitment rates, a smaller high-performing network, lighter monitoring. The fastest defendable budget when the envelope is tight and the design can survive scrutiny on a minimum viable footprint.
Median historical site rates, standard MDR pivotal or PMCF footprint. The scenario most sponsors actually live in, with the contingency a CFO can defend to the board and the cost split country by country.
P25 site rates, maximum monitoring, worst-case IRB lag, slowest activation, longest follow-up. The number you bring to the board so nobody can say "we did not see this coming".
This is the live three-way forecast you build in the room: cost and recruitment for all three scenarios, on one screen, export-ready. Figures below are illustrative for a cardiovascular pivotal.
Illustrative output. Your real cost and recruitment curves are built live against your protocol across the three workshops.
Not a quote you wait three weeks for, a working session. You change the inputs and the cost, sites and recruitment forecasts reflow in front of you.
A real forecast is not one slider. Across the three workshops you tune every assumption that moves the budget. A representative selection:
A traditional CRO quote is a long wait that still leaves you guessing. Eclevar runs it live, with two senior experts in the room, and hands you an itemised, three-scenario budget within 48 hours.
Days to weeks before the first draft quote even comes back.
Quoted as "to be negotiated directly with sites", you get a rule of thumb, roughly 0.8x the CRO budget.
A project total, not what a senior CRA, biostatistician or regulatory lead actually costs.
Change the sample size or add Germany, wait another 4 to 8 weeks for a new scenario.
No historical anchoring, no P25/P75, no conservative case for the board.
Courier, customs, IRB, kit shipment appear mid-execution, risk you discover after you have committed.
Workshop 1: your scope entered on screen, all three scenarios reflow as you watch.
Country-specific grants from a live hospital-tariff database: nurse, clinician, MRI, X-ray, per patient and per visit.
CRO line items priced per role, per hour. You see exactly what you pay for.
Workshops 2 and 3 adjust every assumption, no waiting weeks for a re-quote.
P25/P50/P75 site rates from seven years of delivery, with the conservative case taken seriously.
A clinical-trial veteran and a former TUV SUD reviewer catch the risk and the hidden cost before you commit.
Milo TF gives you a budget. These two tell you whether it is defendable. No account managers, no junior staff: the people who decide whether your design passes a Notified Body and whether your sites actually recruit are with you in every workshop.
A veteran of clinical trial delivery across France, Germany, the UK and Eastern Europe. Nancy knows which sites underdeliver in winter, which ethics committees add eight weeks to start-up, and which PIs are systematically overconfident about recruitment. She is the reason the conservative scenario is taken seriously.
Mark spent years deciding whether clinical evidence was good enough for a CE mark. In the workshop he reads your design the way a Notified Body reviewer will, flagging the gaps that turn into expensive amendments later and the over-engineering you are paying for but do not need.
Eclevar takes the same cardiovascular and MDR expertise that scopes your budget onto the stage at Europe's leading device congresses. Come and pressure-test your trial design with us.
Meet Chems Hachani (CEO), Dr Mark Da Costa (COO, former Notified Body expert), Nancy Boodhun (Director of Operations) and S. Meier Piantanida (Chief Data Officer) at the world's leading interventional cardiovascular course.
Dr Mark Da Costa (COO, former Notified Body expert) joins the panel from 16:30 to 18:30 to discuss how EU MDR is reshaping the path for new structural-heart and cardiovascular devices.
Ready to go? Pay securely and we schedule workshop one straight away, first budget back within 48 hours. Want to ask questions first? Book a no-obligation call with Karina, our Head of Partnerships. No payment required to talk.
Not sure which countries to model, or whether your protocol is ready to cost? Book a no-obligation call. Karina will walk you through how the three workshops work, what to bring to workshop one, and answer anything before you commit. No payment needed to talk.
Book a call with KarinaThe questions sponsors and medical device manufacturers ask most often when scoping CRO and site costs across France, Germany and the UK.
Book workshop one and we build your first three-scenario, country-by-country budget live on Milo TF, then deliver the report within 48 hours. Or send your synopsis ahead and we arrive with the model already roughed in.
